Today: 24 January 2026
Subscribe
Browse Category

NASDAQ:SRPT News 12 January 2026 - 24 January 2026

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

New York, Jan 24, 2026, 05:28 (EST) — Market closed. Sarepta Therapeutics Inc shares climbed in after-hours trading Friday following the announcement of a Jan. 26 update on three-year data for its Duchenne gene therapy, Elevidys. The stock had closed down 3% at $21.13 but later traded near $22.20, a roughly 5% gain. (MarketWatch) The timing couldn’t be more critical.…
24 January 2026
·····
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

New York, Jan 12, 2026, 14:53 EST — Regular session. Sarepta Therapeutics shares dropped roughly 13% to $20.73 in Monday afternoon trading following a disappointing sales forecast for its Duchenne muscular dystrophy gene therapy, Elevidys, in the fourth quarter. This matters because Elevidys has turned into the company’s key swing factor — and a closely watched one at that —…
12 January 2026
····

Stock Market Today

  • Linkhome Holdings Inc. (LHAI) Posts 6.9% ROE, Aligns with Real Estate Sector Average
    January 24, 2026, 9:22 AM EST. Linkhome Holdings Inc. (NASDAQ:LHAI) reported a Return on Equity (ROE) of 6.9% for the trailing twelve months ending September 2025, closely matching the Real Estate industry average of 7.5%. ROE measures net profit generated from shareholders' equity, indicating the company's ability to generate returns on investments from shareholders. With a low debt-to-equity ratio of 0.0053, Linkhome Holdings maintains a minimal leverage position, reducing financial risk despite its modest ROE. While the profitability metric is neither outstanding nor weak, the conservative use of debt suggests the business holds stable prospects. Investors should monitor further financial indicators, as ROE alone does not capture all risks or growth potential.
Go toTop